Global Neuraminidase Inhibitor Market Research Report 2022

Influenza viruses are characterized by two surface glycoproteins i.e. hemagglutinnin and neuraminidase. Neuraminidase are the antigens which play an important role in defining the particular strain of influenza. Dosage and safety of neuraminidase inhibitors are the two main parameters, affecting the growth of neuraminidase inhibitors market. The various symptoms of influenza are cough, running nose, fever, headache, fatigue, chills etc. The neuraminidase are recommended for the treatment of the symptoms after the forty eight hours of start of these symptoms.

There are few neuraminidase inhibitors, being sold in the market. The neuraminidase inhibitors have been classified as zenamivir, oseltamivir, peramivir, leninamivir and few other neuraminidase inhibitors. Zenamivir and oseltamivir are the neuraminidase inhibitors which are being used for the treatment of influenza A or influenza B.

Due to the COVID-19 pandemic, the global Neuraminidase Inhibitor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Neuraminidase Inhibitor market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Neuraminidase Inhibitor landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Zanamivir accounting for % of the Neuraminidase Inhibitor global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.

The global major manufacturers of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, BioCryst and Daiichi Sankyo, etc. In terms of revenue, the global 3 largest players have a % market share of Neuraminidase Inhibitor in 2021.

This report focuses on Neuraminidase Inhibitor volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Neuraminidase Inhibitor market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Global Neuraminidase Inhibitor Market: Segment Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.


Segment by Type


Zanamivir

Oseltamivir

Peramivir

Laninamivir


Segment by Application


Hospital Pharmacies

Drug Stores

Retail Stores

Others

By Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE


By Company


GlaxoSmithKline

Gilead Sciences

F. Hoffman-La Roche

BioCryst

Daiichi Sankyo